Io Biotech Inc (IOBT) Stock Price, Quote & News

Company Profile

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead therapeutic cancer vaccine candidate includes IO102-IO103, which targets cancer cells and immune-suppressive cells in the tumor microenvironment that express indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to...

Industry: Biotechnology

Sector: Healthcare

Phone: 45 70 70 29 80

Website: www.iobiotech.com

Address:

Ole MaalOees Vej 3, Copenhagen N, Copenhagen, Denmark

Doozio Jul. 4 at 3:56 PM

$IOBT chop chop huckleberries let’s bang bro it’s 🐒🍌🧠⏰♾️

0 · Reply

DrUpUpAway Jul. 2 at 3:31 AM

$IOBT Ok EIB second tranche warrants have been priced. 4,221,867 shares at $1.31 They're getting a great deal. I have a feeling this has been musical chairs for rocket ship seats the whole time. Key Euro insiders ie. EIB, Novo, Lundbeck, and other new significant players inbound. Zocca will be kicked to the curb. This thing is about to blast off, can feel the electricity charging the air.

1 · Reply

IPO_Candy Jul. 1 at 5:43 PM

$INMB Closing out the few remaining contracts I had on this one and taking it off my list. Was a good one. Very lucky there was a positive reaction to the PR on Thursday, an unexpected gift for a graceful exit. On to the next one $IOBT

0 · Reply

luigiovine Jul. 1 at 8:14 AM

$IOBT The EIB only makes safe investments, it does not give away 57 million to risky biotech companies. It made an investment where it should earn 10x. Rest assured, your money will increase like that of the EIB. Target price 20$

1 · Reply

luigiovine Jun. 30 at 8:39 PM

$IOBT Insider buys

0 · Reply

texmade2 Jun. 30 at 5:48 PM

$IOBT gap fill ?

0 · Reply

ArbMan Jun. 30 at 4:05 PM

$IOBT 2025Q3 tomorrow. Who is excited?!?!?!?!? I just want to point out, this is also 2H2025 and that in addition to our P3 results in Q3, we are expecting some info from other stuff in 2H. Tomorrow we hit the point where we could get info any day. (Even if it is not a P3 readout, it could be an announcement that we have hit our requisite number of events in the P3 study, or some info for earlier phase studies.)

0 · Reply

DrUpUpAway Jun. 25 at 6:01 PM

$IOBT Second day now of subtle healthy accumulation. Low volume offer/ask side trades. A steady pace of this over the next weeks into data readout reaching the $3S and we should be right on course.

2 · Reply

GCPA Jun. 23 at 7:01 PM

$IOBT Opdualag was approved for 1L advanced Melanona on March 18 2022. Here the revenues since then: 2022: $252 mill 2023: $617 mill 2024: $870 mill (1Q $206MILL; 2Q $235MILL; 3Q $233MILL; 4Q $233MILL). 2025: 1Q $252 mill If Phase 3 results are as they seem to be, IO+Pembro should follow a similar path.

1 · Reply

ArbMan Jun. 23 at 5:58 PM

$IOBT https://www.aktiencheck.de/news/Artikel-IO_Biotech_CEO_Vertrag_aendert_sich_was_steckt_dahinter-18695542 It is in German, but if google translate is accurate, it says the for the CEO's exit package in the event of her leaving as part of the company being acquired, her compensation has gone up, something which often immediately precedes negotiations about an acquisition.... Is something brewing here? I will gladly part with my 100k shares today for $10.70 per share. That's the 10x I am looking for on my $1.07/share investment... Truth be told, $5.35 wouldn't make me cry.

1 · Reply

IO Biotech Announces Participation in Cowen 6th Annual Oncology Innovation Summit and Jefferies Global Healthcare Conference

May 14, 2025, 8:05 AM EDT - 7 weeks ago

IO Biotech Reports First Quarter 2025 Financial Results and Business Highlights

Apr 26, 2025, 3:05 PM EDT - 2 months ago

IO Biotech Showcases Scientific Leadership Through Cancer Vaccines Educational Session at the American Association for Cancer Research (AACR) Annual Meeting 2025

Apr 25, 2025, 1:00 PM EDT - 2 months ago

IO Biotech Presents New Data at AACR 2025 Supporting Dual Mechanism and Immune Activation of Cancer Vaccines IO102-IO103 and IO170

Mar 25, 2025, 4:35 PM EDT - 3 months ago

IO Biotech Announces Acceptance of Abstracts to be Presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Mar 18, 2025, 8:00 AM EDT - 3 months ago

IO Biotech Named Among Fast Company's World's Most Innovative Companies of 2025

Mar 4, 2025, 4:17 PM EST - 4 months ago

IO Biotech Reports 2024 Business Highlights

Feb 23, 2025, 12:07 PM EST - 4 months ago

IO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO Conference

Feb 20, 2025, 8:05 AM EST - 4 months ago

IO Biotech to Present at the 45th Annual Cowen Health Care Conference

Feb 4, 2025, 8:05 AM EST - 5 months ago

IO Biotech Announces Publication of Preclinical Data Investigating Immune-Modulatory Effects of IO112, an Arginase 1-Targeting Therapeutic Cancer Vaccine Candidate

Jan 9, 2025, 8:05 AM EST - 6 months ago

IO Biotech Completes Enrollment in Phase 2 Trial of its Investigational, Off-the-shelf Therapeutic Cancer Vaccine, IO102-IO103, as Neoadjuvant/Adjuvant Treatment for Patients with Resectable Melanoma or Head and Neck Cancer

Dec 20, 2024, 8:05 AM EST - 7 months ago

IO Biotech secures up to €57.5 million in debt financing from the European Investment Bank

Nov 12, 2024, 7:05 AM EST - 8 months ago

IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business Highlights

Nov 11, 2024, 4:05 PM EST - 8 months ago

IO Biotech Announces Participation in Upcoming Investor Conferences

Nov 7, 2024, 10:00 AM EST - 8 months ago

IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA® Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 Study

Oct 4, 2024, 9:00 AM EDT - 9 months ago

IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting

Sep 14, 2024, 2:30 AM EDT - 10 months ago

IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer

Aug 30, 2024, 4:05 PM EDT - 11 months ago

IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma

Aug 13, 2024, 7:05 AM EDT - 11 months ago

IO Biotech Reports Second Quarter 2024 Financial Results and Provides Business Highlights

Jul 25, 2024, 4:05 PM EDT - 1 year ago

IO Biotech Announces New Head and Neck Cohort Data Accepted for Presentation at ESMO Congress 2024

May 23, 2024, 8:30 AM EDT - 1 year ago

IO Biotech to Present at Jefferies Global Healthcare Conference

May 14, 2024, 7:55 AM EDT - 1 year ago

IO Biotech Reports First Quarter 2024 Financial Results and Provides Business Highlights

Apr 24, 2024, 4:30 PM EDT - 1 year ago

IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 15, 2024, 8:30 AM EDT - 1 year ago

IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness

Apr 9, 2024, 12:00 PM EDT - 1 year ago

IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103

Apr 5, 2024, 8:30 AM EDT - 1 year ago

IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer

Mar 6, 2024, 4:11 PM EST - 1 year ago

IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Mar 5, 2024, 4:40 PM EST - 1 year ago

IO Biotech Announces 2023 Fourth-Quarter and Year-End Results

Feb 26, 2024, 4:05 PM EST - 1 year ago

IO Biotech to Present at 44th Annual Cowen Health Care Conference

Jan 3, 2024, 3:04 AM EST - 1 year ago

IO Biotech: A Phase 3 Company Getting No Respect

Dec 21, 2023, 8:30 AM EST - 1 year ago

IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial

Nov 13, 2023, 8:12 AM EST - 1 year ago

IO Biotech Announces 2023 Third Quarter Results

Nov 13, 2023, 8:00 AM EST - 1 year ago

IO Biotech Appoints Helen Collins, MD, to its Board of Directors

Nov 10, 2023, 8:00 AM EST - 1 year ago

IO Biotech Completes Enrollment of 380 Patients in Pivotal Phase 3 Trial in Advanced Melanoma

Nov 1, 2023, 8:30 AM EDT - 1 year ago

IO Biotech Presents Three Posters at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Oct 23, 2023, 1:00 AM EDT - 1 year ago

Encouraging Preliminary Data from a Phase 2 Trial Evaluating IO102-IO103 in Combination with Pembrolizumab for First-line Treatment of Patients with Non-small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck Presented at the European Soci

Oct 3, 2023, 4:30 PM EDT - 1 year ago

IO Biotech Announces Three Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Sep 12, 2023, 8:05 AM EDT - 1 year ago

IO Biotech Announces New Data Related to its IO102-IO103 Therapeutic Cancer Vaccine Presented Today at the IASLC 2023 World Conference on Lung Cancer

Aug 11, 2023, 8:30 AM EDT - 2 years ago

IO Biotech Announces 2023 Second Quarter Results

Aug 11, 2023, 8:05 AM EDT - 2 years ago

IO Biotech Appoints Heidi Hunter to its Board of Directors

Aug 8, 2023, 8:05 AM EDT - 2 years ago

IO Biotech Announces Abstract Accepted for Poster Presentation at ESMO Congress 2023

Aug 7, 2023, 8:30 AM EDT - 2 years ago

IO Biotech, Inc. Announces $75 Million Private Placement Financing

Jul 28, 2023, 8:05 AM EDT - 2 years ago

IO Biotech Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial at University of California Davis Comprehensive Cancer Center

Jul 25, 2023, 4:05 PM EDT - 2 years ago

IO Biotech Announces Abstract Accepted for Mini Oral Presentation at IASLC 2023 World Conference on Lung Cancer

Jul 18, 2023, 4:05 PM EDT - 2 years ago

IO Biotech Strengthens Executive Management and US Presence with Appointment of Qasim Ahmad, MD, as Chief Medical Officer

Jun 14, 2023, 8:00 AM EDT - 2 years ago

IO Biotech Announces Achievement of Significant Phase 3 Clinical Trial Recruitment Milestone

Jun 1, 2023, 8:30 AM EDT - 2 years ago

IO Biotech Appoints Christine Richter, Ph.D., MBA, as Senior Vice President, Commercial and Program Lead

May 30, 2023, 4:35 PM EDT - 2 years ago

IO Biotech to Present at the Jefferies Healthcare Conference

May 11, 2023, 4:05 PM EDT - 2 years ago

IO Biotech Announces 2023 First-Quarter Results

Mar 14, 2023, 4:11 PM EDT - 2 years ago

IO Biotech Announces 2022 Fourth-Quarter and Year-End Results

Doozio Jul. 4 at 3:56 PM

$IOBT chop chop huckleberries let’s bang bro it’s 🐒🍌🧠⏰♾️

0 · Reply

DrUpUpAway Jul. 2 at 3:31 AM

1 · Reply

IPO_Candy Jul. 1 at 5:43 PM

0 · Reply

luigiovine Jul. 1 at 8:14 AM

1 · Reply

luigiovine Jun. 30 at 8:39 PM

$IOBT Insider buys

0 · Reply

texmade2 Jun. 30 at 5:48 PM

$IOBT gap fill ?

0 · Reply

ArbMan Jun. 30 at 4:05 PM

0 · Reply

DrUpUpAway Jun. 25 at 6:01 PM

$IOBT Second day now of subtle healthy accumulation. Low volume offer/ask side trades. A steady pace of this over the next weeks into data readout reaching the $3S and we should be right on course.

2 · Reply

GCPA Jun. 23 at 7:01 PM

1 · Reply

ArbMan Jun. 23 at 5:58 PM

1 · Reply

texmade2 Jun. 23 at 1:48 PM

$IOBT 1.60 around the corner.

0 · Reply

ArbMan Jun. 18 at 5:43 PM

$IOBT During the push to clear delisting, I sold 1620 shares (of my 100k shares) at $1.27. I immediately put in a bid to buy them back at $1.02, thinking either we'd clear delisting or I'd make a bit of cash. Maybe if I really got lucky, both. Once we cleared delisting, I bumped the bid up to buy them back at $1.26, because I really wanted the shares back, but don't like buying anything for more than I sold it for. Today the order filled, and I am back up to my original 100k shares. That's a heck of a lot of effort to make $16.20 lol. (Average net price in is $1.07 per share). Now I'm ready to go back to sitting tight and waiting for news.

0 · Reply

ArbMan Jun. 17 at 1:45 PM

$IOBT Q3 starts in just under 2 weeks. At that point, results could come any day. I am really excited to see how Phase 3 plays out. Of course, that is also the second half of the year, so at that point we could get news on some earlier stage trial progress too, but the Phase 3 is the big show right now.

0 · Reply

GCPA Jun. 16 at 4:50 PM

$IOBT Last monthly follow-up. On may 27, at Cowen, the CMO said that they had ALMOST reached 226 events. Let's suppose it took two weeks more, till today. Then: Patients have already reached 18 months of minimum follow-up (last enrolled, mid-December 2023) and more than 28 months of median follow-up (225 already enrolled on June 14 2023, so 55% have 24 months at least; the first was enrolled in May 2022, so it has 37 months). And remember: KEYNOTE-006: at minimum follow-up of 6 months and median follow up of 7'9 months, they had events in 60% of patients enrolled (502 out of 834). RELATIVITY-047: at minimum follow-up of 8'7 months and median follow up of 19'3 months they had events in 61'2% of patients enrolled (437 out of 714), including 57'5% in Opdualag arm and 64'9% in Nivo arm. So we reached 226 events (events in 55'5% of patients) after doubling Rel-047 minimum f-up and with 10 months more of median f-up. Looks strong.

1 · Reply

texmade2 Jun. 16 at 8:14 AM

$IOBT gap fill 1.14 ?

0 · Reply

Notnotshort Jun. 13 at 2:48 PM

$IOBT wtf is going on lol

1 · Reply

Will_Birkin Jun. 13 at 2:15 PM

$IOBT wow what happened

1 · Reply

Notnotshort Jun. 12 at 2:22 PM

$IOBT https://www.linkedin.com/posts/ccit-dk_dienstagsseminar-activity-7338805551415361536-S9yX?utm_source=share&utm_medium=member_desktop&rcm=ACoAADIQDZIBt023QVPJQ5cQSVEErAuZnz1mSmA Mads will hold a seminar about our vax technology in a university in Germany. The professor who initiated this has a PhD in Immunology and worked together with Mads when he studied in Copenhagen. He also focuses his research on Melanoma. There are several papers they worked on together in the past, so they know each other pretty well I guess. He seems to be convinced that this approach might work, otherwise he wouldn't have invited Mads. Share price is certainly too low considering the lenght of the trial and the gigantic market opportunity. IF it works in 1L, it might work in Neoadjuvant/adjuvant setting as well, where the market opportunity is much bigger than in advanced melanoma.

1 · Reply

ArbMan Jun. 11 at 4:00 PM

$IOBT I am really looking forward to them scheduling a presentation some time on or after July 1. At that point, I'll be watching every one live, because any one July 1 to September 30 could have our Phase 3 results.

1 · Reply

Notnotshort Jun. 7 at 12:44 PM

$IOBT Interesting! Started looking through the trial protocol one more time and found this (gem?). A re-estimation prior to enrollment was planned and included enrollment rate AND censoring rate. So they actually had information about censoring when they almost had 300 patients and they decided to increase n not based on higher than usual censoring rate, but due to this here, take from Section 17.1 "The total sample size will be increased to 380, based on a new empirical distribution for the progression-free survival combining the two treatment arms. The empirical distribution was derived from early blinded observations in the current study and three historical trials including KEYNOTE-006, CheckMate-067 and RELATIVITY-047 (22,24,97), which has a prolonged tail of survival curve indicating non-proportional hazard assumption, comparing to the original exponential distribution assumption. 1/2

2 · Reply

ArbMan Jun. 6 at 6:56 PM

$IOBT I am really hoping to someday see this stock popping out annual dividends the size of my initial investment.

0 · Reply

DubK Jun. 6 at 3:30 PM

$PDSB I would think a very important catalyst would be $IOBT phase 3 data in Q3. Also a cancer vaccine. If that data hits, it may finally change the image of cancer vaccines. There’s been such a dark cloud around this sector & has been completely written off by so many investors that if this actually hits, it can bring much needed $$ to this sector again. We’d be the next big fish in phase 3 that could attract A LOT of attention. So let’s go IOBT 🙌🏾

2 · Reply

Market Cap	98.16M
Revenue (ttm)	0.00
Net Income (ttm)	-95.49M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	182,800
Avg Vol	157,960
Day's Range	N/A - N/A
Shares Out	65.88M
Stochastic %K	79%
Beta	0.36
Analysts	Strong Sell
Price Target	$9.50